Apple to Manufacture Full US-Bound iPhone 17 Lineup in India, Report Says
The iPhone 17 is due to debut next month.
According to Bloomberg, citing people with knowledge of the matter, the tech giant is expanding its iPhone production in India at five factories, including two plants that were opened recently, and producing all four iPhone 17 models in the Asian nation. The India expansion is part of Apple's efforts to reduce its dependence on China for the phones it is selling in the U.S. While India faces an extra 25% levy for buying Russian oil on top of the 25% previously announced tariffs, consumer electronic imports into the U.S. are so far exempt from levies.
Apple didn't immediately respond to a request for comment.
Apple shares have lost almost 8% of their value since the start of the year amid worries about its stalling progress in artificial intelligence and the hit from the Trump administration's tariffs. They are little changed in premarket trading.
Read the original article on Investopedia
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Masimo sues US Customs over approval of Apple Watch imports
By Blake Brittain WASHINGTON (Reuters) -Medical monitoring technology company Masimo sued U.S. Customs and Border Protection on Wednesday over a decision by the agency that allowed Apple to import Apple Watches with blood-oxygen reading technology during a patent dispute between the companies. Masimo said in the lawsuit in Washington, D.C., federal court that Customs improperly determined that Apple can import watches with pulse oximetry technology, reversing its own decision from last year without notifying Masimo. Masimo told the court that it learned of the agency's August 1 decision only after Apple announced it would reintroduce blood-oxygen reading to its watches last week. Spokespeople for Apple and Customs did not immediately respond to requests for comment. A Masimo spokesperson declined to comment. Irvine, California-based Masimo has accused Apple of hiring away its employees and stealing its pulse oximetry technology to use in its Apple Watches. Masimo has separately sued Apple for patent infringement and trade secret theft in ongoing federal court cases. Masimo convinced the U.S. International Trade Commission to block imports of Apple's Series 9 and Ultra 2 smartwatches in 2023 based on a determination that Apple's technology for reading blood oxygen levels infringed Masimo's patents. Apple has continued to sell Customs-approved redesigned watches without pulse oximetry since the ITC's decision. Apple said on Aug. 14 that it would reintroduce its smartwatches' blood-oxygen reading capabilities with approval from Customs. Masimo said the agency's decision to approve the watches without input from Masimo or any "meaningful justification" deprived the company of its rights. "CBP's function is to enforce ITC exclusion orders, not to create loopholes that render them ineffective," Masimo said. Masimo asked the Washington court to halt the agency's ruling and continue to block Apple from selling watches with the blood-oxygen feature.
Yahoo
32 minutes ago
- Yahoo
Is Wall Street Bullish or Bearish on PTC Stock?
Headquartered in Boston, Massachusetts, and carrying a market capitalization of approximately $24.7 billion, PTC Inc. (PTC) delivers an extensive suite of software solutions, spanning computer-aided design modeling, product lifecycle management, data orchestration, and experience creation products. Over the past 52 weeks, PTC stock has climbed 20%, outpacing the S&P 500 Index ($SPX), which rose 16.1% during the same stretch. Year-to-date (YTD), the stock has advanced 13.3%, maintaining its edge over the SPX's 9.7% gain. More News from Barchart Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Apple Expects $1.1 Billion Tariff Hit in 4th Quarter After $800 Million Q3 Hit; CEO Tim Cook Warns 'Many Factors That Could Change' Cathie Wood Is Buying BLSH Stock After the Bullish IPO. Should You? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Within the technology sector, however, PTC has slightly trailed the S&P 500 Technology Sector SPDR (XLK), which recorded a 20.3% gain over the past year. Although, on a YTD basis, PTC has exceeded XLK's 14.5% growth, signifying consistent momentum. Momentum accelerated on July 31, when PTC shares rose 6.1%, following a day after the announcement of its fiscal third-quarter 2025 results, which surpassed Wall Street expectations. Revenue for the period increased 24.2% year over year (YoY) to $643.9 million, comfortably above the analyst estimate of $582.4 million. Adjusted EPS climbed 67.3% annually to $1.64 and surpassed the Street's forecast. For the fiscal year 2025, ending in September, analysts forecast PTC to achieve EPS growth of 47.4%, reaching $5.41 on a diluted basis. The company has demonstrated a consistent pattern of outperforming consensus estimates across the past four quarters. Among 19 analysts covering PTC stock, the consensus rating is a "Strong Buy," an upgrade from a 'Moderate Buy' rating a month back. The current consensus consists of 13 "Strong Buy" ratings, one "Moderate Buy," and five 'Hold' recommendations. The current analyst sentiment has grown slightly more bullish compared with three months ago, when 12 analysts held "Strong Buy" ratings. On July 31, BMO Capital raised its price target on PTC to $231 from $187, maintaining an 'Outperform' rating, citing fiscal Q3 results that were "better than feared" and noting modest improvements in deal trends. The same day, Barclays PLC (BCS) lifted its price target from $203 to $233, upholding its 'Overweight' rating. The upward revision followed closely on the heels of the company's earnings release for Q3. The mean price target of $226.61 represents an 8.8% premium to PTC's current price levels. Meanwhile, the Street-high price target of $250 suggests a potential upside of 20%. On the date of publication, Sristi Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
42 minutes ago
- Yahoo
Masimo sues US Customs over approval of Apple Watch imports
By Blake Brittain WASHINGTON (Reuters) -Medical monitoring technology company Masimo sued U.S. Customs and Border Protection on Wednesday over a decision by the agency that allowed Apple to import Apple Watches with blood-oxygen reading technology during a patent dispute between the companies. Masimo said in the lawsuit in Washington, D.C., federal court that Customs improperly determined that Apple can import watches with pulse oximetry technology, reversing its own decision from last year without notifying Masimo. Masimo told the court that it learned of the agency's August 1 decision only after Apple announced it would reintroduce blood-oxygen reading to its watches last week. Spokespeople for Apple and Customs did not immediately respond to requests for comment. A Masimo spokesperson declined to comment. Irvine, California-based Masimo has accused Apple of hiring away its employees and stealing its pulse oximetry technology to use in its Apple Watches. Masimo has separately sued Apple for patent infringement and trade secret theft in ongoing federal court cases. Masimo convinced the U.S. International Trade Commission to block imports of Apple's Series 9 and Ultra 2 smartwatches in 2023 based on a determination that Apple's technology for reading blood oxygen levels infringed Masimo's patents. Apple has continued to sell Customs-approved redesigned watches without pulse oximetry since the ITC's decision. Apple said on Aug. 14 that it would reintroduce its smartwatches' blood-oxygen reading capabilities with approval from Customs. Masimo said the agency's decision to approve the watches without input from Masimo or any "meaningful justification" deprived the company of its rights. "CBP's function is to enforce ITC exclusion orders, not to create loopholes that render them ineffective," Masimo said. Masimo asked the Washington court to halt the agency's ruling and continue to block Apple from selling watches with the blood-oxygen feature. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
